Valence ロゴ
人気
ログイン
Loading data for RHHBF — first visit, this takes a few seconds.

ウォッチリストに追加

Roche Holding AG

OTC Markets OTCQX: RHHBF · リアルタイム株価 · USD
467.00
+2.00 (0.43%)
終値時点： Aug 26, 2026, 12:44 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

Roche Holding AG（RHHBF）の株価・分析・データ

0.43%
買気配462.75
時価総額372.09B
売上高（TTM）62.96B
純利益（TTM）12.34B
0.35
19.15
24.39
31.47
PBR（TTM）9.22
PSR（TTM）5.91
決算発表日n/a
売気配480
出来高18
平均出来高（20日）103
始値468.00
前日終値465.00
当日レンジ467.00 - 471.00
52週レンジ301.27 - 514.08
アナリストn/a
目標株価n/a
配当$12.4 (2.58%)
権利落ち日2026年3月12日

RHHBFについて

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for ...

[続きを読む]
業種 Drug Manufacturers - General
セクター Healthcare
IPO日 Aug 3, 2012
従業員数 n/a
上場取引所 OTC Markets OTCQX
ティッカー RHHBF
ウェブサイト https://www.roche.com
企業情報の全文

業績

2025年のRocheの売上高は63.36Bで、前年の62.4Bから1.54%の増加でした。 利益は12.88Bで、55.61%の増加でした。

財務諸表
news image

12時間前 · GuruFocus.com

Eli Lilly Clears Big Hurdle in Alzheimer's Fight

A simpler diagnostic tool could widen Alzheimer's testing access

news image

1日前 · Investor's Business Daily

Jazz Sparks On Its New Plan To Take On Roche; Hint: It's In Cancer

Jazz stock bounced off its buy zone Tuesday after the FDA approved its drug, Ziihera, to treat a form of stomach cancer.

news image

1日前 · Zacks

Top Stock Reports for Berkshire Hathaway, Roche & RTX

Berkshire Hathaway, Roche and RTX headline today's research, with earnings drivers, growth catalysts and risks shaping their outlooks.

news image

1日前 · Motley Fool

2 Stocks That Could Capitalize on the GLP-1 Boom

They aren't the most prominent names in the GLP-1 space, but they are worth a second look.

news image

1日前 · BioPharma Dive

New Jazz cancer drug approval could drive blockbuster sales

Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.

2ページ中1ページ